학술논문
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry
Document Type
article
Author
Jatuworapruk, Kanon; Montgomery, Anna; Gianfrancesco, Milena; Conway, Richard; Durcan, Laura; Graef, Elizabeth R; Jayatilleke, Aruni; Keen, Helen; Kilian, Adam; Young, Kristen; Carmona, Loreto; Cogo, Adriana Karina; Duarte‐García, Alí; Gossec, Laure; Hasseli, Rebecca; Hyrich, Kimme L; Langlois, Vincent; Lawson‐Tovey, Saskia; Malcata, Armando; Mateus, Elsa F; Schafer, Martin; Scirè, Carlo Alberto; Sigurdardottir, Valgerdur; Sparks, Jeffrey A; Strangfeld, Anja; Xavier, Ricardo M; Bhana, Suleman; Gore‐Massy, Monique; Hausmann, Jonathan; Liew, Jean W; Sirotich, Emily; Sufka, Paul; Wallace, Zach; Machado, Pedro M; Yazdany, Jinoos; Grainger, Rebecca; Robinson, Philip C
Source
ACR Open Rheumatology. 4(11)
Subject
Language
Abstract
ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.